| 153 | 30 | 53 |
| 下载次数 | 被引频次 | 阅读次数 |
目的分析瑞舒伐他汀对早期糖尿病肾病(DN)患者微炎症状态和氧化应激的影响及肾脏保护作用,为早期DN的临床治疗提供参考。方法选取2015年6月至2018年6月就诊,且符合纳入标准的120例早期DN患者为研究对象。按照随机数字表法将其分为观察组和对照组,各60例。对照组患者采取常规治疗,观察组在常规治疗的基础上予瑞舒伐他汀治疗。于治疗前后检测并比较肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、血尿素氮(BUN)、血肌酐(SCr)水平及尿白蛋白排泄率(UAER)在2组间的差异。结果治疗后,2组TNF-α、hs-CRP、IL-6、MDA、SCr、UAER水平均明显低于治疗前(P<0.05),且观察组明显低于对照组(P<0.05);观察组BUN水平明显低于治疗前及对照组(P<0.05);2组SOD、GSH-Px水平明显高于治疗前(P<0.05),且观察组明显高于对照组(P<0.05)。结论瑞舒伐他汀可有效改善早期DN患者的微炎症状态,降低氧化应激水平,且对肾脏具有一定的保护作用。
Abstract：AIM To analyze the effects of rosuvastatin on the microinflammatory state, oxidative stress and renal protective effects in patients with early diabetic nephropathy(DN), and to provide references for the clinical treatment of early DN. METHODS A total of 120 patients with early DN in our hospital and met the inclusion criteria were selected from June 2015 to June 2018, and they were divided into observation group(n=60) and control group(n=60) according to random number table. The control group was treated with routine treatment, and the observation group was treated with rosuvastatin based on the control group. The levels of tumor necrosis factor-α(TNF-α), hypersensitive C reactive protein(hs-CRP), interleukin-6(IL-6), malondialdehyde(MDA), superoxide dismutase(SOD), glutathione peroxidase(GSH-Px), blood urea nitrogen(BUN), serum creatinine(SCr) and urinary albumin excretion rate(UAER) were detected and compared between the 2 groups before and after treatment. RESULTS After treatment, the levels of TNF-α, hs-CRP, IL-6, MDA, SCr and UAER in the 2 groups were significantly lower than those before treatment(P<0.05), and the observation group was significantly lower than the control group(P<0.05). The level of BUN in the observation group was significantly lower than that before treatment and in the control group(P<0.05). The levels of SOD and GSH-Pxin the 2 groups were significantly higher than those before treatment(P<0.05), and the observation group was significantly higher than the control group(P<0.05). CONCLUSION Rosuvastatin can effectively improve the microinflammatory state and decrease the oxidative stress level of patients with early DN,which has a certain protective effect on the kidney.
[1] 张丽,马雪,王俭勤.IGF系统与糖尿病肾病关系的研究进展[J].中国中西医结合肾病杂志,2017,18(3):274.
[2] 黄乙芸,王欣,张月莉,等.糖尿病肾病微炎症与营养不良的研究进展[J].现代中西医结合杂志,2018,27(11):1247.
[3] 余勋.瑞舒伐他汀防治心血管疾病的研究进展[J].中国药房,2016,27(29):4174.
[4] 孔畅,陈东峰,宋振华,等.芪归药对治疗糖尿病肾病的理论探讨[J].辽宁中医杂志,2018,45(2):267.
[5] ABDEL-DAIM M M,ABDEEN A.Protective effects of rosuvastatin and vitamin E against fipronil-mediated oxidative damage and apoptosis in rat liver and kidney[J].Food Chem Toxicol,2018,114:69.
[6] 王叶菊,李燕妮,鲁乃宏.阿托伐他汀钙片联合阿魏酸哌嗪片治疗糖尿病肾病的疗效观察[J].现代药物与临床,2016,31(4):467.
[7] ARMSTRONG J A,CASH N J,OUYANG Y,et al.Oxidative stress alters mitochondrial bioenergetics and modifies pancreatic cell death independently of cyclophilin D,resulting in an apoptosis-to-necrosis shift[J].J Biol Chem,2018,293(21):8032.
[8] 杨晓丽,韩秋霞,邬明辉,等.糖尿病肾病及其他肾脏疾病患者血浆高敏C反应蛋白表达[J].中华实用诊断与治疗杂志,2018,32(5):434.
[9] 张瑶,汪力,高芳,等.阿托伐他汀对糖尿病肾病微炎症状态的影响[J].西部医学,2016,28(2):215.
[10] 吴海娟,牛小娟,罗晓红.他汀类药物防治糖尿病肾病的研究进展[J].华南国防医学杂志,2017,31(2):141.
[11] 李美,滕涛,李檬.玉液合剂对2型糖尿病患者SOD、GSH-PX和MDA的影响[J].现代中西医结合杂志,2016,25(23):2593.
[12] 管小玲.厄贝沙坦联合胰激肽原酶肠溶片治疗早期糖尿病性肾病观察[J].江西医药,2016,51(10):1064.
[13] 张俊,江泽慧,黄国明,等.瑞舒伐他汀对大鼠造影剂急性肾损伤的保护作用及机制[J].科学技术与工程,2016,16(13):23.
基本信息:
DOI：10.19577/j.1007-4406.2019.06.001
中图分类号:R587.2;R692.9
引用信息:
[1]陈平,胡望远.瑞舒伐他汀对早期糖尿病肾病患者微炎症状态和氧化应激的影响及肾脏保护作用[J].中国临床药学杂志,2019,28(06):401-404.DOI:10.19577/j.1007-4406.2019.06.001.
基金信息:
浙江省医药卫生科技项目(编号2014ZDA027)
2019-11-25
2019-11-25